SMS Pharma shares surged nearly 18% after its associate company VKT Pharma received US FDA approval for reformulated Ranitidine tablets, marking the drug’s return to the US market after five years.
SMS Pharma shares surged nearly 18% after its associate company VKT Pharma received US FDA approval for reformulated Ranitidine tablets, marking the drug’s return to the US market after five years.